Virginia Retirement Systems ET AL lowered its position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 32.9% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,200 shares of the biotechnology company’s stock after selling 21,700 shares during the quarter. Virginia Retirement Systems ET AL owned 0.23% of Enanta Pharmaceuticals worth $2,069,000 as of its most recent SEC filing.
Other hedge funds have also recently made changes to their positions in the company. GAM Holding AG acquired a new position in shares of Enanta Pharmaceuticals in the 2nd quarter worth approximately $108,000. Municipal Employees Retirement System of Michigan raised its holdings in shares of Enanta Pharmaceuticals by 3.5% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 3,280 shares of the biotechnology company’s stock worth $118,000 after buying an additional 110 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Enanta Pharmaceuticals by 5.8% in the 2nd quarter. SG Americas Securities LLC now owns 4,354 shares of the biotechnology company’s stock worth $157,000 after buying an additional 237 shares in the last quarter. BNP Paribas Arbitrage SA raised its holdings in shares of Enanta Pharmaceuticals by 62.9% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,409 shares of the biotechnology company’s stock worth $159,000 after buying an additional 1,702 shares in the last quarter. Finally, Louisiana State Employees Retirement System acquired a new position in shares of Enanta Pharmaceuticals in the 2nd quarter worth approximately $205,000. Institutional investors own 66.97% of the company’s stock.
A number of equities analysts have recently issued reports on the company. Royal Bank Of Canada increased their target price on Enanta Pharmaceuticals from $54.00 to $58.00 and gave the stock an “outperform” rating in a report on Tuesday, November 21st. Zacks Investment Research raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th. JMP Securities increased their target price on Enanta Pharmaceuticals from $40.00 to $53.00 in a report on Wednesday, October 4th. BidaskClub raised Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, August 11th. Finally, J P Morgan Chase & Co reissued an “overweight” rating and issued a $38.00 target price (up from $32.00) on shares of Enanta Pharmaceuticals in a report on Wednesday, August 9th. Three equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $46.25.
Enanta Pharmaceuticals (NASDAQ:ENTA) last released its quarterly earnings results on Monday, November 20th. The biotechnology company reported $1.86 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.13 by ($0.27). Enanta Pharmaceuticals had a net margin of 17.23% and a return on equity of 6.46%. The business had revenue of $75.93 million for the quarter, compared to analyst estimates of $73.80 million. During the same period in the prior year, the business earned ($0.09) earnings per share. The company’s revenue for the quarter was up 491.3% on a year-over-year basis. equities research analysts anticipate that Enanta Pharmaceuticals Inc will post -1.57 EPS for the current year.
TRADEMARK VIOLATION NOTICE: “Virginia Retirement Systems ET AL Trims Holdings in Enanta Pharmaceuticals Inc (ENTA)” was first reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/05/virginia-retirement-systems-et-al-trims-holdings-in-enanta-pharmaceuticals-inc-enta.html.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
What are top analysts saying about Enanta Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Enanta Pharmaceuticals Inc and related companies.